Introduction: Many men live with chronic prostate diseases, such as Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). Medications widely prescribed for BPH and CP/ CPPS can cause sexual dysfunction and depression, which may increase patient visits to hospitals. The purpose of this study is to determine whether Thermobalancing Therapy (TT) and Dr. Allen’s Therapeutic Device (DATD) can be used as the first-line treatment preventing the development of new health disorders often resulting from taking medications for BPH and CP/CPPS.
Methods: This is a retrospective analysis of 2 observational clinical trials on thermobalancing therapy and DATD. Cohorts of 124 men with BPH and 45 men with CP/CPPS were treated with DATD and compared to the control groups without DATD. The dynamics of pain, urinary symptoms, Quality of Life (QoL), and Prostate Volume (PV) were assessed before and after treatment.
Results: In men with Benign Prostatic Hyperplasia (BPH), Dr. Allen’s Therapeutic Device (DATD) reduced PV from 45 ml to 31 ml (P<0.001) and decreased urinary symptoms from 14.3 to 4.9 (P<0.001). DATD reduced pain score from 10.3 to 3.5 (P<0.001) in men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). QoL was improved in both treatment groups. In the control groups, no positive changes were observed.
Conclusions: The use of Thermobalancing therapy as a monotherapy reduces the abnormal prostate size and provides chronic pelvic pain relief in men with BPH and CP/CPPS, improving their QoL. This at-home treatment with DATD reduces the need for long-term courses of BPH and CP/CPPS medications preventing retrograde ejaculation, sexual dysfunction, depression, and other health disorders. The wider use of DATD in healthcare systems will decrease male visits to hospitals, diminishing the risks of contracting a viral infection and transmitting it to others during a coronavirus outbreak or another pandemic.
Published Date: 2020-07-28; Received Date: 2020-07-11